Reify Health vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Reify Health raised $220M Series D at $4.8B valuation; OneStudyTeam and Care Access accelerate clinical trial site operations and decentralized enrollment; $407M total raised to bridge diversity gap in trials.
About
Reify Health is a clinical trial acceleration company whose two platform arms — OneStudyTeam and Care Access — address the two biggest friction points in clinical research: site operations efficiency and patient enrollment reach. OneStudyTeam provides workflow software that automates the administrative burden on clinical research sites, enabling faster startup, better sponsor-site collaboration, and compliant data capture throughout trial execution. Care Access operates a decentralized clinical trial infrastructure that brings research directly to patients in underserved communities, expanding the diversity and geographic reach of clinical study populations.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.